In 2006, Deltex Medical submitted an application to the Centers for Medicare and Medicaid Services (CMS) to reverse a pre-existing national non-coverage decision for esophageal Doppler monitoring (EDM). The original decision pre-dated the release of Deltex Medical's EDM technology, the CardioQ™. As part of their review of esophageal Doppler guided fluid management, CMS commissioned a technology assessment from the Agency for Healthcare Research and Quality (AHRQ). Further details on this document are given here.

Based on the technology assessment and its internal review CMS determined that EDM is "reasonable and necessary" and should be covered for reimbursement in two important patient populations. In the announcement of the reversal of the pre-existing national coverage decision CMS Acting Administrator Leslie V. Norwalk noted.

"Today's decision reflects CMS' commitment to using evidenced based approaches to provide Medicare beneficiaries with reasonable and necessary medical technologies as they evolve through innovation in the market place. As we developed this decision, we used the best available medical evidence – in the form of randomized controlled clinical trials – to re-evaluate our position on this important non-invasive method of caring for patients in intensive care situations."

Deltex Medical has engaged the services of Princeton Reimbursement Group to provide professional reimbursement advice and documentation to support our customer's reimbursement process. This reimbursement hotline number is: 877 725 9767

The information given on these pages provides further detail of coverage, coding and payment as they relate to EDM. If you have any questions on reimbursement, please call the above support line or email us on usreimbursement@deltexmedical.com

© Deltex Medical | Contact Us | Terms and Conditions | Welcome